The Clinical Trial Agreement

Part of Principal Investigator (PI) Training: The Business of Running a Site.

About 4 minutes. Free, in your language, no account needed.

Why this matters

The clinical trial agreement is signed by your institution, negotiated by people you may never meet, and it commits you to things. Section 2.5.1 even contemplates it as the document that records your agreement to the protocol, in place of a protocol signature.

You do not need to negotiate it. You do need to know which clauses will land on your desk in eighteen months.

The clauses that reach the investigator

Direct access. The agreement will grant the sponsor, auditors and regulatory authorities access to trial-related records. This is not a concession — §2.12.14 and §3.16.4 require it, and your participants consented to it. Check that it is present rather than negotiating it away.

Records retention and the custodian. Sections 2.12.11 to 2.12.13 require essential records to be maintained, retained for the longest applicable period, and a named person given to the sponsor as responsible for them. The agreement usually sets the period. Two traps from Module 10 apply: E6(R3) states no period in years, so check what your regional law and the contract actually say; and the named custodian should be an institutional role that outlasts individuals.

Publication rights. The single clause most worth reading yourself. A reasonable term lets the sponsor review a manuscript for a defined, short period and protect genuine confidential information; it does not let them suppress a result. A term giving the sponsor an unqualified veto over publication is one to escalate, because it puts your name on work you may not be able to report.

Subject injury and indemnity. Who pays for the care of a participant harmed by the trial, and how does a participant actually access that. You will be asked this in a consent discussion, by someone who deserves a straight answer.

Termination. What happens to participants mid-treatment if the study stops. Module 8's §2.6.1 duty to inform participants and ensure appropriate therapy and follow-up does not depend on the contract, so it is worth knowing what the contract funds.

Confidentiality and data protection. What you may say, to whom, and how participant data is handled across borders.

Results and the participant

Section 2.9.3 provides for informing participants of the trial results and, as applicable, the treatment they received, when available and according to their preference. Where a lay summary is provided it should be non-promotional. If the agreement is silent on who produces one and when, ask at start-up rather than discovering the answer is "nobody" three years later.

Five questions before you let it be signed

You are not the lawyer. These five are the ones only you can judge, and they take ten minutes:

  1. Does the budget cover the work in the protocol, including my own time?
  2. Can I meet every operational commitment — timelines, recruitment, data entry windows — with the site I actually have?
  3. Is the publication clause one I can live with having my name on?
  4. Is direct access granted, and is the retention period and custodian something my institution can honor?
  5. Is subject-injury care clear enough that I can explain it to a participant in one sentence?

If any answer is no, that is a conversation for now, not for month eight — the same rule as the protocol in Module 3.

Key takeaways